此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

高流量治疗在长期氧疗中的效果 (HILOT)

2026年11月16日 更新者:Magnus Ekström、Skane University Hospital

高流量疗法在长期氧疗 (HILOT) 中的效果:一项多中心、基于注册的随机临床试验

This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).

研究概览

详细说明

This is a registry-based, randomized, controlled clinical trial of patients with LTOT for COPD or ILD recruited using the Swedish National Registry for Respiratory Failure (Swedevox) in collaboration with a research network within the Swedish Respiratory Society. The trial evaluates the effect of added high-flow oxygen therapy nighttime to the regular low-flow oxygen therapy compared with regular low-flow oxygen therapy alone up to one year.

The purpose of this project is to improve evidence-based treatment of people with chronic respiratory failure, currently about 2000 patients annually in Sweden, who have high risk of adverse events and mortality.

研究类型

介入性

注册 (估计的)

310

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Örebro、瑞典、70185
        • 招聘中
        • Department of Heart, Lung and Clinical Physiology, Örebro University Hospital
        • 接触:
          • Josefin Sundh, MD, PhD
    • Blekinge County
      • Karlskrona、Blekinge County、瑞典、37185
        • 招聘中
        • Research Unit, Blekinge University of Technology
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 40 years or older
  • Ongoing LTOT: prescribed for at least 15 hours per day; and since at least 28 days as registered in Swedevox
  • COPD or ILD as main underlying reason for LTOT
  • Oxygen concentrator as stationary oxygen source in the home including night-time
  • Body mass index (BMI) < 35 kg/m2

Exclusion Criteria:

  • Current or previous treatment with home HFOT
  • Current treatment with home mechanical ventilation
  • Current treatment with home CPAP
  • Hospitalized during the last 2 weeks
  • Current smoking or contact with flames
  • Self-reported average use of the LTOT < 15h per day (24 hours)
  • PaCO2 (breathing air at rest) > 8 kPa
  • Strong clinical suspicion of obstructive sleep apnea (OSA) or obesity-related hypoventilation syndrome (OHS) (as judged by the responsible staff)
  • Inability to participate in the study procedures (as judged by the staff)
  • Not eligible for continuing LTOT due to other reason (as judged by the staff)
  • Expected survival less than 3 months (as judged by the staff)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:High-flow oxygen therapy

Intervention arm

Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.

有源比较器:Low-flow oxygen therapy

Comparison arm

Standard care with low-flow oxygen therapy in accordance with clinical routine.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Time to first hospitalization or death from all causes
大体时间:1 year

Time to first hospitalization or death from all causes during 1 year after randomization in people with COPD (assessed using nationwide registry data)

1 year

次要结果测量

结果测量
措施说明
大体时间
Time to first all-cause hospitalization or all-cause death
大体时间:1 year

Time to first all-cause hospitalization or all-cause death in people with ILD (assessed using nationwide registry data)

1 year
Rate of hospitalizations or death from all causes
大体时间:1 year

Rate of hospitalizations or death from all causes assessed using nationwide registry data

1 year
Hospitalization rate from all causes
大体时间:1 year

Hospitalization rate from all causes assessed using nationwide registry data

1 year
Hospitalization rate from respiratory disease
大体时间:1 year

Hospitalization rate from respiratory disease assessed using nationwide registry data

1 year
Number of hospitalized days
大体时间:1 year

Number of hospitalized days from all-causes, respiratory and cardiovascular disease using nationwide registry data

1 year
Hospitalization rate from cardiovascular disease
大体时间:1 year

Hospitalization rate from cardiovascular disease assessed using nationwide registry data

1 year
Number of admissions to intensive care unit (ICU)
大体时间:1 year

Number of admissions to ICU assessed using nationwide registry data

1 year
Number of days in ICU
大体时间:1 year

Number of days in ICU assessed using nationwide registry data

1 year
Mortality rate from all causes
大体时间:1 year

The mortality rate from all causes assessed using nationwide registry data

1 year
Mortality rate from respiratory disease
大体时间:1 year

The mortality rate from respiratory disease assessed using nationwide registry data

1 year
Mortality rate from cardiovascular disease
大体时间:1 year

The mortality rate from cardiovascular disease assessed using nationwide registry data

1 year
Time to first exacerbation
大体时间:1 year

Time to first exacerbation after randomisation, defined as time to first dispensed antibiotics and/or oral corticosteroids, ED-visit or hospitalization for exacerbation assessed using self-reported and registry data

1 year
Number of exacerbations
大体时间:1 year

Number of exacerbations of all severity assessed using self-reported and registry data

1 year
Incidence of cardiovascular disease
大体时间:1 year

Incidence of cardiovascular disease assessed using nationwide registry data

1 year
Need for home mechanical ventilation
大体时间:1 year

Need for starting home mechanical ventilation assessed using nationwide registry data

1 year
Rate of withdrawal of long-term oxygen therapy
大体时间:1 year

Rate of withdrawal of long-term oxygen therapy assessed using nationwide registry data

1 year
Adverse events
大体时间:3 and 12 months

Self-reported adverse events since study start assessed using a postal questionnaire.

3 and 12 months
Primary care utilization
大体时间:1 year

Self-reported number of primary care contacts since the start of the study assessed using a postal questionnaire.

1 year
Health-related quality of life
大体时间:3 and 12 months

Self-reported health-related quality of life assessed using the EuroQol Five Dimensions - Five Levels (EQ5D-5L) questionnaire.

3 and 12 months
Health status
大体时间:3 and 12 months

Self-reported health status assessed using the and the COPD Assessment Test (CAT) questionnaire.

3 and 12 months
Breathlessness at exertion
大体时间:3 and 12 months

Self-reported exertional breathlessness assessed using the Dyspnoea Exertion Scale (DES) questionnaire.

3 and 12 months
Breathlessness
大体时间:3 and 12 months

Self-reported breathlessness assessed using the Dyspnea-12 questionnaire.

3 and 12 months
Sleep quality
大体时间:3 and 12 months

Self-reported sleep quality assessed using the modified Basic Nordic Sleep Questionnaire.

3 and 12 months
Physical activity
大体时间:3 and 12 months

Self-reported level of physical activity assessed using the modified Grimby-Frändin questionnaire.

3 and 12 months
Change in health status
大体时间:3 and 12 months

Self-reported change in perceived health status assessed using the Global Impression of Change (GIC) scale.

3 and 12 months
Nasal symptoms
大体时间:3 and 12 months

Self-reported nasal symptoms assessed using the modified Björklund questionnaire.

3 and 12 months

其他结果措施

结果测量
措施说明
大体时间
Patient preference for continuing the treatment
大体时间:3 and 12 months

Patients' self-reported patient preference for continuing the treatment assessed using postal questionnaire.

3 and 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年6月10日

初级完成 (估计的)

2028年12月1日

研究完成 (估计的)

2029年12月1日

研究注册日期

首次提交

2024年1月17日

首先提交符合 QC 标准的

2024年2月6日

首次发布 (实际的)

2024年2月7日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

IPD cannot be shared due to restrictions in the current ethical approval. Pseudonymized IPD can be shared upon reasonable request and separate ethical approval.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅